Challenges in cancer control in Australia

Ian N Olver
Med J Aust 2007; 186 (11): . || doi: 10.5694/j.1326-5377.2007.tb01051.x
Published online: 4 June 2007

Despite advances in treatment, the greatest gains in cancer control are achieved through prevention

The translation of basic cancer research on cell growth to the clinic has resulted in a paradigm shift in cancer treatment by providing new therapeutic targets. The initial successes — the monoclonal antibodies trastuzumab and rituximab — have improved the survival of patients with breast cancer and lymphoma, as has the small molecule imatinib mesylate in chronic myeloid leukaemia; all have less toxicity than conventional cytotoxics.1 The challenge is to fund these new high-cost drugs. Although targeted drugs can be limited to the specific patient populations expressing the appropriate target, further funding is then required to screen patients for those targets. New models of cost- and risk-sharing between governments and industry must evolve to pay for these developments.

  • The Cancer Council Australia, Sydney, NSW.


  • 1. Ross JS, Schenkein DP, Pietrusko R, et al. Targeted therapies for cancer 2004. Am J Clin Pathol 2004; 122: 598-609.
  • 2. Quackenbush J. Microarray analysis and tumour classification. N Engl J Med 2006; 354: 2463-2472.
  • 3. Smith L, Lind MJ, Welham KJ, Cawkwell L; Cancer Biology Proteomics Group. Cancer proteomics and its application to discovery of therapy response markers in human cancer. Cancer 2006; 107: 232-241.
  • 4. Access Economics. Exceptional returns: the value of investing in health R&D in Australia. Canberra: Australian Society for Medical Research, 2003.
  • 5. Australian Institute of Health and Welfare. National public health expenditure report 2004–05. Health and Welfare Expenditure Series No. 29. (AIHW Cat. No. HWE 36.) Canberra: AIHW, 2007.
  • 6. Begg S, Vos T, Goss J, et al. The burden of disease and injury in Australia, 2003. Canberra and Brisbane: AIHW and University of Queensland, 2007 [in press].
  • 7. Australian Institute of Health and Welfare. 2004 National Drug Strategy Household Survey: first results. (AIHW Cat. No. PHE 57.) Canberra: AIHW, 2005.
  • 8. VicHealth Centre for Tobacco Control. Tobacco control: a blue chip investment in public health. Melbourne: Anti-Cancer Council of Victoria, 2003.
  • 9. Applied Economics. Returns on investment in public health: an epidemiological and economic analysis. Canberra: Commonwealth Department of Health and Ageing, 2003.
  • 10. Australian Bureau of Statistics. National Health Survey: Aboriginal and Torres Strait Islander results, Australia, 1995. (ABS Cat. No. 4806.0.) Canberra: ABS, 1999.
  • 11. Australian Electoral Commission. 2005/06 annual financial disclosure returns. Canberra: AEC, Jan 2007.
  • 12. International Agency for Research on Cancer. IARC handbooks of cancer prevention. Vol. 6. Weight control and physical activity. Lyon: World Health Organization, 2002.
  • 13. Shields M. Nutrition: findings from the Canadian Community Health Survey. Issue No. 1. Overweight Canadian children and adolescents. Component of Statistics Canada Catalogue No. 82-620-MWE2005001. Ottawa: Statistics Canada, 2005.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.